EdgarLookup

Bio Green Med Solution, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Bio Green Med Solution, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Financials Insiders
-273.9%
Return on Assets
Net income ÷ assets
-2.88x
Debt-to-Equity
Total liabilities ÷ equity
-100%
Revenue Growth
Year over year

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $0 Mar 30, 2018
FY2017 Dec 31, 2016 $843.0K Mar 30, 2018
FY2016 Dec 31, 2015 $1.94M Mar 31, 2017
FY2015 Dec 31, 2014 $1.73M Mar 29, 2016
FY2014 Dec 31, 2013 $1.08M Mar 31, 2015
FY2013 Dec 31, 2012 $69.0K Mar 26, 2014
FY2011 Dec 31, 2011 $699.0K Mar 30, 2012
FY2012 Dec 31, 2010 $112.0K Apr 1, 2013
FY2011 Dec 31, 2009 $911.0K Mar 30, 2012

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 ($11.21M) Nov 26, 2025
FY2024 Dec 31, 2023 ($22.56M) Nov 26, 2025
FY2023 Dec 31, 2022 ($21.20M) Mar 21, 2024
FY2022 Sep 30, 2022 ($5.10M) Nov 29, 2023
FY2022 Jun 30, 2022 ($4.58M) Nov 29, 2023
FY2022 Dec 31, 2021 ($18.46M) Nov 29, 2023
FY2022 Sep 30, 2021 ($4.76M) Nov 29, 2023
FY2021 Dec 31, 2020 ($8.45M) Mar 30, 2022
FY2020 Dec 31, 2019 ($7.83M) Mar 1, 2021
FY2019 Dec 31, 2018 ($7.29M) Mar 5, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 ($12.00M) Nov 26, 2025
FY2024 Dec 31, 2023 ($25.45M) Nov 26, 2025
FY2023 Dec 31, 2022 ($27.66M) Mar 21, 2024
FY2022 Dec 31, 2021 ($22.39M) Nov 29, 2023
FY2022 Sep 30, 2021 ($5.70M) Nov 29, 2023
FY2021 Dec 31, 2020 ($10.64M) Mar 30, 2022
FY2020 Dec 31, 2019 ($9.68M) Mar 1, 2021
FY2019 Dec 31, 2018 ($9.55M) Mar 5, 2020
FY2018 Dec 31, 2017 ($9.49M) Mar 28, 2019
FY2017 Dec 31, 2016 ($14.15M) Mar 30, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $4.09M Nov 26, 2025
FY2024 Dec 31, 2023 $8.81M Nov 26, 2025
FY2023 Dec 31, 2022 $28.05M Mar 21, 2024
FY2022 Sep 30, 2022 $31.57M Nov 29, 2023
FY2022 Jun 30, 2022 $35.90M Nov 29, 2023
FY2022 Mar 31, 2022 $40.18M Nov 29, 2023
FY2022 Dec 31, 2021 $43.14M Nov 29, 2023
FY2022 Sep 30, 2021 $45.29M Nov 29, 2023
FY2021 Dec 31, 2020 $36.80M Mar 30, 2022
FY2020 Dec 31, 2019 $15.31M Mar 1, 2021

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $6.27M Nov 26, 2025
FY2024 Dec 31, 2023 $8.20M Nov 26, 2025
FY2023 Dec 31, 2022 $7.62M Mar 21, 2024
FY2022 Sep 30, 2022 $4.58M Nov 29, 2023
FY2022 Jun 30, 2022 $5.26M Nov 29, 2023
FY2022 Mar 31, 2022 $6.34M Nov 29, 2023
FY2022 Dec 31, 2021 $5.44M Nov 29, 2023
FY2022 Sep 30, 2021 $3.70M Nov 29, 2023
FY2021 Dec 31, 2020 $3.54M Mar 30, 2022
FY2020 Dec 31, 2019 $3.61M Mar 1, 2021

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 ($2.17M) Nov 26, 2025
FY2024 Dec 31, 2023 $607.0K Nov 26, 2025
FY2024 Dec 31, 2022 $15.94M Nov 26, 2025
FY2022 Sep 30, 2022 $22.50M Nov 29, 2023
FY2022 Jun 30, 2022 $29.53M Nov 29, 2023
FY2022 Mar 31, 2022 $33.84M Nov 29, 2023
FY2023 Dec 31, 2021 $37.69M Mar 21, 2024
FY2022 Sep 30, 2021 $41.59M Nov 29, 2023
FY2022 Dec 31, 2020 $33.26M Nov 29, 2023
FY2021 Dec 31, 2019 $11.70M Mar 30, 2022

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 (504) Nov 26, 2025
FY2024 Dec 31, 2023 (6,419) Nov 26, 2025
FY2022 Dec 31, 2022 (1) Mar 8, 2023
FY2022 Dec 31, 2021 (2) Nov 29, 2023
FY2022 Sep 30, 2021 0 Nov 29, 2023
FY2021 Dec 31, 2020 (3) Mar 30, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 (504) Nov 26, 2025
FY2024 Dec 31, 2023 (6,419) Nov 26, 2025
FY2023 Dec 31, 2022 (27) Mar 21, 2024
FY2022 Dec 31, 2021 (2) Nov 29, 2023
FY2022 Sep 30, 2021 0 Nov 29, 2023
FY2021 Dec 31, 2020 (3) Mar 30, 2022

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 $3.14M Nov 26, 2025
FY2024 Dec 31, 2023 $3.38M Nov 26, 2025
FY2023 Dec 31, 2022 $18.35M Mar 21, 2024
FY2022 Dec 31, 2021 $36.56M Nov 29, 2023
FY2021 Dec 31, 2020 $33.41M Mar 30, 2022
FY2020 Dec 31, 2019 $11.89M Mar 1, 2021
FY2019 Dec 31, 2018 $17.50M Mar 5, 2020
FY2018 Dec 31, 2017 $23.91M Mar 28, 2019
FY2018 Dec 31, 2016 $16.52M Mar 28, 2019
FY2017 Dec 31, 2015 $20.44M Mar 30, 2018